Cingulate

Cingulate Equity Growth

The Year-over-Year Equity Growth of Cingulate (CING) as of Nov 11, 2026 is -66.35 %. In the previous year, Year-over-Year Equity Growth was 208.53 % — a change of -131.82% (lower).

Equity Growth

-66.35 %

YoY

-131.82%

Last updated:

Year-over-Year Equity Growth of Cingulate is 2025 -66.35 % . Year-over-Year Equity Growth of Cingulate was 2024 208.53 % . It decreases by -131.82% lower compared to the previous year.

The Cingulate Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2020
109.85 USD
Jan 1, 2021
1,512.73 USD
Jan 1, 2022
-81.38 USD
Jan 1, 2023
-276.95 USD
Jan 1, 2024
208.53 USD
Jan 1, 2025
-66.35 USD
The Cingulate Equity Growth history
YEAREquity GrowthYoY
-66.35 %-131.82%
208.53 %-175.29%
-276.95 %+240.34%
-81.38 %-105.38%
1,512.73 %+1,277.07%
109.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Year-over-Year Equity Growth of Cingulate is -66.35 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Cingulate since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cingulate

All Key Metrics — Cingulate